Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Phase I study of CART-ddBCMA in R/R multiple myeloma

Matthew Frigault • 3 Jun 2022
ASCO 2022
Multiple Myeloma CAR-T CART-ddBCMA

Matthew J. Frigault, MD, Harvard Medical School, Boston, MA, discusses the safety and efficacy results of a Phase I study of CART-ddBCMA, an autologous anti-BCMA CAR-T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder, in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Matthew Frigault

0:53
Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
Matthew Frigault • 10 Dec 2023
0:58
Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault • 12 Dec 2023
Prophylaxis and management of CRS & ICANS
Bianca Santomasso et al. • 14 Apr 2023
Rapid CAR manufacture
Caron Jacobson et al. • 14 Apr 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals